Patents Examined by Karl J. Puttlitz
  • Patent number: 11529352
    Abstract: The addition of a selective, fast-acting, short half-life CDK 4/6 inhibitor in a very specific dosage regimen to the combination of chemotherapy with a checkpoint inhibitor provides superior results in the treatment of a tumor or cancer. The unexpected discovery is that the short pulsatile specifically-timed administration of a selective, fast-acting, short half-life CDK 4/6 inhibitor during administration of the chemotherapy portion of the triple combination therapy has a profound effect on the immune cells in the cancer microenvironment.
    Type: Grant
    Filed: June 5, 2019
    Date of Patent: December 20, 2022
    Assignee: G1 Therapeutics, Inc.
    Inventors: Jessica A. Sorrentino, Anne Y. Lai, Jay C. Strum, Patrick Joseph Roberts
  • Patent number: 11525001
    Abstract: Anti-CD8 antibodies, radiolabeled anti-CD8 antibodies, fluorescently labeled anti-CD8 antibodies and their use in imaging are provided herein. Included are methods of detecting the presence of CD8 proteins in a subject or sample.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: December 13, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Jason T. Giurleo, Dangshe Ma, William Olson, Richard Tavare, Gavin Thurston
  • Patent number: 11517530
    Abstract: Provided herein are extracellular vesicle (EV) (a.k.a. exosome) compositions for specifically targeting the delivery of a therapeutic agent to particular cells and/or tissues in a subject, as well as methods of making and methods of using said compositions. The compositions and methods disclosed herein are useful for targeted drug delivery in the treatment of diseases in which a cell surface receptor is overexpressed, such as, for example, cancer.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: December 6, 2022
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Jing-Hung Wang, Alexis Forterre, A. C. Matin, Alain Delcayre
  • Patent number: 11492413
    Abstract: The present invention relates to a Fab fragment based switchable antibody system for generating site-specific antibody conjugates. Methods are described for the attachment of molecules to specific sites the Fab fragment and for the attachment of the Fab fragment to a target molecule (e.g., an antibody) directed against any desired target antigen (tumor, bacterial, fungal, viral, parasitic etc.) The attachment is via binding of the Fab fragment to an epitope linked to the target molecule.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: November 8, 2022
    Assignee: Temple University—Of The Commonwealth System of Higher Education
    Inventors: Rongsheng E. Wang, Zhigang Lyu, Haley L. Wissler
  • Patent number: 11485792
    Abstract: An antibody or antigen-binding portion thereof which binds to PSMA and comprises a heavy chain variable domain comprising the sequence given in SEQ ID NO:33, wherein SEQ ID NO:33 is: EVQLVQSGX9E X11KKPGASVKV SCKX24SGYTFT EYTIHWVX38QA X41 GKGLEWIGN INPNX55GGTTY NOKFEDRX68TX70 TVDKSTSTAY MELSSLRSED TAVYYCAAGW NFDYWGOGTT VTVSS wherein: X9 is A or P X11 is V or L X24 is A or T X38 is R or K X41 is P or H X55 is N or Q X68 is V or A; and X70 is I or L whereby the heavy chain variable domain comprises up to 3 amino acid sequence modification(s) between positions 1-30, 36-49, 67-98 and 105-115 of SEQ ID NO: 33. The invention also provides compounds that include the antibody or antigen-binding portion thereof, such as conjugates, and their use in the treatment or diagnosis of diseases, in particular cancers, particularly prostate cancer.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: November 1, 2022
    Inventors: Timothy David Jones, Robert George Edward Holgate, Francis Joseph Carr
  • Patent number: 11479538
    Abstract: The present invention provides compounds of Formula (I): a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, a solvate thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: October 25, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventor: Saleem Ahmad
  • Patent number: 11478472
    Abstract: Disclosed is use of NK3R antagonists for the therapeutic treatment leptin-related disease.
    Type: Grant
    Filed: February 20, 2020
    Date of Patent: October 25, 2022
    Assignee: Ogeda SA
    Inventors: Hamid Hoveyda, Graeme Fraser
  • Patent number: 11459398
    Abstract: Provided are conjugates including a targeting moiety that binds to a cell surface molecule of a target cell and a target cell surface-editing enzyme. Also provided are compositions and kits that include the conjugates, as well as methods of using the conjugates. Methods of making conjugates are also provided.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: October 4, 2022
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Elliot C. Woods, Han Xiao, Carolyn R. Bertozzi, Melissa Gray
  • Patent number: 11447486
    Abstract: The present invention relates to benzimidazole derivatives having the general formula I, wherein n is 0 or 1; X1 and X2 are independently, at each occurrence, CR5 or N; Y is C1-C6 alkylene, wherein alkylene is optionally substituted with one to two C1-C3 alkyl groups; R1 is selected from the group consisting of hydrogen, halogen, C1-C6 alkoxy, —NH2, —NHR6, —NR7R8 and —NH—(R9)n—R10, n being 0 or 1; R2 is selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, —NH2, —NHR6, —NR7R8 and —NH—(R9)n—R10; R3 is selected from the group consisting of hydrogen, hydroxyl, OR11, —NR7R8, C1-C6 alkoxy, C1-C6 alkyl, C3-C10 cycloalkyl, C1-C3 haloalkyl, —C(O)NHR11, aryl, heteroaryl and heterocyclyl, wherein each of said cycloalkyl, aryl, heteroaryl and heterocyclyl is optionally and independently substituted with one to four Ra groups; and R4 is selected from the group consisting of —NH2, —N(R12)(V)pR13, —NH(V)p—OR14, —NHC(O)R15, and groups of formula 1a shown below, and their use in the treatment of diseases, in
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: September 20, 2022
    Assignees: INSTITUT PASTEUR KOREA, QURIENT CO., LTD.
    Inventors: Jaeseung Kim, Seohyun Ahn, Yeejin Jeon, Dongsik Park, Young-In Yang, Doohyung Lee, Saeyeon Lee, Jiye Ahn, Jeongjun Kim, Kiyean Nam, Sunhee Kang, Minjung Seo, Mooyoung Seo, Jeongjea Seo, Sung-Jun Han, Jung Hwan Kim, Sangchul Lee, Gahee Choi, Yunmi Lee
  • Patent number: 11446388
    Abstract: The invention relates to a conjugate comprising (a) an amatoxin comprising (i) an amino acid 4 with a 6?-deoxy position; and (ii) an amino acid 8 with an S-deoxy position; (b) a BCMA-binding moiety comprising (i) the variable domains of humanized antibody J22.9-ISY, and (ii) a heavy chain constant region comprising a D265C mutation; and (c) a protease-cleavable linker linking said amatoxin and said target-binding moiety. The invention furthermore relates to a pharmaceutical composition comprising such conjugate, particularly for use in the treatment of multiple myeloma.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: September 20, 2022
    Assignee: HEIDELBERG PHARMA RESEARCH GMBH
    Inventors: Torsten Hechler, Michael Kulke, Christian Lutz, Andreas Pahl, Christoph Müller, Werner Simon, Anikó Pálfi
  • Patent number: 11439637
    Abstract: Provided herein is are methods of using 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof and a bispecific antibody specifically binding to human B cell maturation antigen (BCMA) and to human CD3? (CD3) provided herein, in treating, preventing or managing multiple myeloma.
    Type: Grant
    Filed: May 22, 2019
    Date of Patent: September 13, 2022
    Assignee: Celgene Corporation
    Inventors: Daniel W. Pierce, Lilly L. Wong
  • Patent number: 11433128
    Abstract: This disclosure provides cell surface anchoring antigen conjugates, formulations comprising cell surface anchoring antigen conjugates, and methods of using the same for treating cancer.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: September 6, 2022
    Inventor: Tianxin Wang
  • Patent number: 11414417
    Abstract: A crystalline form I of a compound represented by Formula (VII-1): having characteristic peaks appearing at lattice spacing (d) of 7.34, 5.66, 5.53, 5.30, 5.02, 4.66, 4.37, 4.28, 4.06, 3.68, 3.62, 3.47, 3.36, 3.30, 3.16, 3.11, 3.03, 2.99 and 2.50 ? in the powder X-ray diffraction pattern.
    Type: Grant
    Filed: February 18, 2020
    Date of Patent: August 16, 2022
    Assignee: MEIJI SEIKA PHARMA CO., LTD.
    Inventors: Takao Abe, Takeshi Furuuchi, Yoshiaki Sakamaki, Nakako Mitsuhashi, Yumiko Saito
  • Patent number: 11413342
    Abstract: The present application relates to antibodies that bind to small molecules such as cyclophosphamide, ifosfamide, and analogs thereof, and immunological assays for determining the presence and/or quantifying the amount of cyclophosphamide and/or ifosfamide in a sample. By way of example, such immunological assays can be used for environmental testing.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: August 16, 2022
    Assignee: Becton, Dickinson and Company
    Inventor: Brian P. Dwyer
  • Patent number: 11406633
    Abstract: The present disclosure relates to the field of pharmacy, particularly to a Wnt inhibitor and a PD-1 inhibitor for use in the treatment of cancer. Specifically, the disclosure relates to a pharmaceutical combination comprising a Wnt inhibitor, or a pharmaceutically acceptable salt thereof, and a PD-1 inhibitor, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer, to a method for the treatment of cancer that involves administering the combination and to the use of the combination for the manufacture of a medicament for the treatment of cancer.
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: August 9, 2022
    Inventors: Jason Russell Dobson, Susan Moody, Margaret Elise McLaughlin
  • Patent number: 11395796
    Abstract: Methods of administering immunoconjugates that bind to CD37 (e.g., IMGN529) in combination with antibodies that bind to CD20 are provided. The methods comprise administering an anti-CD37 immunoconjugate (e.g., IMGN529) and an anti-CD20 antibody to a person in need thereof, for example, a cancer patient.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: July 26, 2022
    Assignee: Debiopharm International, S.A.
    Inventors: Angela Romanelli, Rodrigo R. Ruiz-Soto, Jose Ponte, Jutta Deckert, Jan Pinkas
  • Patent number: 11395812
    Abstract: The present invention relates to a docetaxel albumin nanoparticle pharmaceutical composition, a preparation method therefor, and a use thereof for manufacturing drugs for treating cancer. The pharmaceutical composition comprises docetaxel, albumin and amino acid(s), wherein the weight ratio between albumin and docetaxel is no more than 50, preferably is 20:1 to 1:1, and the weight ratio between amino acid(s) and docetaxel is not less than 0.5, preferably is 1:1 to 20:1.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: July 26, 2022
    Assignee: SICHUAN KELUN PHARMACEUTICAL RESEARCH INSTITUTE CO. LTD.
    Inventors: Zhengxing Su, Likai Yang, Dong Zhao, Jing Zhou, Fengying Shan, Lichun Wang, Jingyi Wang
  • Patent number: 11382982
    Abstract: The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumours and haematological malignancies expressing HER2, in particular breast cancer, gastric cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell cancer or osteosarcoma, and acute lymphoblastic leukaemia. In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of human solid tumours with HER2 IHC 2+ or 1+ and HER2 FISH negative tissue status. Advantageously, the present invention relates to duocarmycin-containing ADCs for use in the treatment of triple negative breast cancer (TNBC).
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: July 12, 2022
    Assignee: Byondis B.V.
    Inventors: Willem Dokter, Peter Johannes Goedings, Gijsbertus Franciscus Maria Verheijden, Patrick Henry Beusker
  • Patent number: 11376239
    Abstract: Provided herein are pharmaceutical combinations comprising (a) a B-Raf inhibitor, or a pharmaceutically acceptable salt thereof, (b) at least one mitogen activated protein kinase (MEK) inhibitor, or a pharmaceutically acceptable salt thereof, and (c) an epidermal growth factor receptor (EGFR) inhibitor or a pharmaceutically acceptable salt thereof; and optionally at least one pharmaceutically acceptable carrier; methods for preparing the pharmaceutical combinations, and the uses of the pharmaceutical combinations in the treatment of proliferative diseases, such as cancer.
    Type: Grant
    Filed: September 24, 2019
    Date of Patent: July 5, 2022
    Assignee: ARRAY BIOPHARMA INC
    Inventors: Giordano Caponigro, Zhu Alexander Cao
  • Patent number: 11364303
    Abstract: The invention relates to polypeptides, antibodies, and antigen-binding fragments thereof, that comprise an engineered cysteine for site-specific conjugation.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: June 21, 2022
    Assignee: Pfizer Inc.
    Inventors: Madan Katragadda, Russell Dushin, Lawrence Nathan Tumey